Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Hana Mekonnen"'
Autor:
Steen Knudsen, Anker Hansen, Marie Foegh, Steen Petersen, Hana Mekonnen, Lin Jia, Preeti Shah, Victoria Martin, Gregory Frykman, Roberto Pili
Publikováno v:
PLoS ONE, Vol 18, Iss 8 (2023)
Purpose Dovitinib is a receptor tyrosine kinase inhibitor of VEGFR1-3, PDGFR, FGFR1/3, c-KIT, FLT3 and topoisomerase 1 and 2. The drug response predictor (DRP) biomarker algorithm or DRP-Dovitinib is being developed as a companion diagnostic to dovit
Externí odkaz:
https://doaj.org/article/959bcf4274864e8ba19888a0ae507918
Autor:
Derry Green, Denis Burger, Hana Mekonnen, Kazem Kazempour, Nader Pourhassan, Shide Badri, Paul J Maddon, Kush Dhody
Publikováno v:
HIV clinical trials. 19(3)
Background PRO 140 is a humanized monoclonal antibody targeting CCR5 with potent antiviral activity in patients with CCR5-tropic HIV-1 infection. In phase 2b studies, we evaluated the long-term efficacy, safety, and tolerability of PRO 140 monotherap
Autor:
Hana Mekonnen, Kazem Kazempour, Hadine Joffe, Joel Lippman, JoAnn V. Pinkerton, Sailaja Bhaskar
Publikováno v:
Menopause (New York, N.y.)
Objective Sleep disturbances are common among women in midlife; prevalence increases among perimenopausal/postmenopausal women with vasomotor symptoms. Paroxetine 7.5 mg is the only nonhormonal treatment that has been approved in the United States fo
Autor:
Sailaja Bhaskar, Kazem Kazempour, Joel Lippman, Hana Mekonnen, David Portman, Andrew M. Kaunitz
Publikováno v:
Menopause (New York, N.y.)
Supplemental digital content is available in the text.
Objective Two phase 3, randomized, placebo-controlled trials demonstrated that low-dose paroxetine 7.5 mg reduced the frequency and severity of vasomotor symptoms (VMS) associated with menop
Objective Two phase 3, randomized, placebo-controlled trials demonstrated that low-dose paroxetine 7.5 mg reduced the frequency and severity of vasomotor symptoms (VMS) associated with menop
Autor:
Hana Mekonnen, David Portman, Sailaja Bhaskar, Kazem Kazempour, James A. Simon, Andrew M. Kaunitz, Joel Lippman
Publikováno v:
Menopause (New York, N.Y.). 20(10)
The efficacy and safety of low-dose paroxetine 7.5 mg for the treatment of menopausal vasomotor symptoms were evaluated in two multicenter, double-blind, placebo-controlled, phase 3 studies of 12 and 24 weeks' duration.Postmenopausal women were rando